Back to Search Start Over

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data.

Authors :
Szturz P
Budíková M
Vermorken JB
Horová I
Gál B
Raymond E
de Gramont A
Faivre S
Source :
Oral oncology [Oral Oncol] 2017 Nov; Vol. 74, pp. 68-76. Date of Electronic Publication: 2017 Sep 27.
Publication Year :
2017

Abstract

Objectives: The hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) ligand/receptor axis has been implicated in pathogenesis of malignant diseases including squamous cell carcinoma of the head and neck (SCCHN). Overexpression of c-MET has been reported as a common molecular abnormality in SCCHN, although its prognostic and predictive value remains to be validated.<br />Methods: We systematically searched literature for studies evaluating c-MET expression on immunohistochemistry in newly diagnosed, non-metastatic SCCHN. The c-MET expressing cases were classified into three categories according to predefined cut-off values for positivity. Our aim was to assess the prevalence of c-MET expression and its relationship with selected clinicopathological variables.<br />Results: Twenty-eight studies with 2019 cases were included. Relative frequencies of c-MET expression above cut-off levels I, II, and III were 81.8%, 63.8%, and 46.2%, respectively. Differences between these three values were statistically significant (p<1.0×10 <superscript>-6</superscript> ). Above cut-off level II, c-MET positivity was associated with worse overall survival (p=4.0×10 <superscript>-6</superscript> ), positive nodal status (p=1.0×10 <superscript>-4</superscript> ), higher disease stage (p=7.0×10 <superscript>-4</superscript> ), older age (p=2.1×10 <superscript>-3</superscript> ), disease recurrence (p=2.0×10 <superscript>-2</superscript> ), and primary tumour localization in the oral cavity (p=2.3×10 <superscript>-2</superscript> ). Above cut-off level III, c-MET positivity was associated with worse disease-free or progression-free survival (p=9.0×10 <superscript>-6</superscript> ), p16 negativity (p=2.4×10 <superscript>-4</superscript> ), worse overall survival (p=4.0×10 <superscript>-4</superscript> ), positive epidermal growth factor receptor (EGFR) status (p=7.2×10 <superscript>-4</superscript> ), and larger primary tumours (p=4.6×10 <superscript>-3</superscript> ).<br />Conclusion: In SCCHN, immunohistochemical overexpression of c-MET above cut-off levels III and particularly II was associated with inferior survival outcomes and advanced disease. Moreover, it represents a promising predictive biomarker for c-MET targeting, yet the optimal scoring method remains to be defined.<br /> (Copyright © 2017 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1879-0593
Volume :
74
Database :
MEDLINE
Journal :
Oral oncology
Publication Type :
Academic Journal
Accession number :
29103754
Full Text :
https://doi.org/10.1016/j.oraloncology.2017.09.009